Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

BrainsWay Ltd

Healthcare US BRSYF

16.84USD
0.00(0%)

Last update at 2026-06-18T20:00:00Z

Day Range

13.5413.55
LowHigh

52 Week Range

3.4013.55
LowHigh

Fundamentals

  • Previous Close 16.84
  • Market Cap627.80M
  • Volume300
  • P/E Ratio75.28
  • Dividend Yield-%
  • EBITDA5.86M
  • Revenue TTM52.23M
  • Revenue Per Share TTM1.37
  • Gross Profit TTM 39.39M
  • Diluted EPS TTM0.18

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 8.35M 3.46M -3.94600M -13.03400M -6.41900M
Minority interest - - - - -
Net income 8.26M 2.92M -4.19700M -13.34900M -6.46200M
Selling general administrative 25.46M 14.24M 5.32M 6.85M 5.78M
Selling and marketing expenses - 6.79M 16.46M 18.20M 15.88M
Gross profit 42.63M 30.58M 23.48M 20.05M 23.06M
Reconciled depreciation 1.54M 1.77M 1.34M 1.53M 1.69M
Ebit 4.68M 3.59M -3.89800M -12.68300M -4.99900M
Ebitda 6.34M 5.36M -2.56100M -11.14800M -3.31300M
Depreciation and amortization 1.66M 1.77M 1.34M 1.53M 1.69M
Non operating income net other - - - - -
Operating income 4.68M 1.39M -4.95900M -12.68300M -4.99900M
Other operating expenses 51.85M 39.62M 36.74M 39.86M 34.66M
Interest expense 2.39M 0.13M 0.05M 0.05M 1.42M
Tax provision 0.08M 0.54M 0.36M 0.32M 0.04M
Interest income 5.60M 2.48M 2.17M 1.11M 0.23M
Net interest income 3.39M 1.12M 1.88M -0.35100M -1.42000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.08M 0.54M 0.25M 0.32M 0.04M
Total revenue 56.53M 41.02M 31.79M 27.18M 29.66M
Total operating expenses 37.95M 29.19M 28.44M 32.73M 28.06M
Cost of revenue 13.90M 10.44M 8.31M 7.13M 6.60M
Total other income expense net 3.67M 2.07M 1.01M -0.24400M -0.33300M
Discontinued operations - - - - -
Net income from continuing ops 7.63M 2.92M -8.19100M -13.34900M -6.46200M
Net income applicable to common shares - - - -13.34900M -6.46200M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 112.94M 94.32M 62.97M 64.48M 75.73M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 5.69M 1.30M 1.98M 1.56M 1.77M
Total liab 34.67M 32.00M 21.39M 19.08M 18.41M
Total stockholder equity 73.24M 62.31M 41.58M 45.40M 57.32M
Deferred long term liab - - - - -
Other current liab 8.11M 5.66M 8.27M 5.31M 5.27M
Common stock 0.43M 0.41M 0.37M 0.36M 0.36M
Capital stock 0.43M 0.41M 0.37M 0.36M 0.36M
Retained earnings -90.76684M -98.38100M -101.30200M -97.10500M -83.75600M
Other liab - - - 10.69M 9.09M
Good will - - - - -
Other assets - - 0.00000M 1.04M 0.95M
Cash 67.97M 69.34M 10.52M 47.58M 16.92M
Cash and equivalents - - - - -
Total current liabilities 22.17M 15.35M 9.76M 8.14M 9.07M
Current deferred revenue 10.55M 5.73M 2.50M 1.48M 2.19M
Net debt -61.14669M -63.72100M -10.04900M -47.09300M -16.16700M
Short term debt 1.07M 0.82M 0.23M 0.23M 0.50M
Short long term debt - - - - -
Short long term debt total 6.82M 5.62M 0.47M 0.49M 0.75M
Other stockholder equity 162.25M 162.47M 144.70M 144.33M 142.91M
Property plant equipment - - - 5.35M 9.33M
Total current assets 84.91M 79.67M 55.47M 58.09M 65.45M
Long term investments 14.34M - - - -
Net tangible assets - - - 45.40M 57.33M
Short term investments 1.43M 0.00000M 35.47M 0.27M 40.43M
Net receivables 4.11M 4.60M 3.78M 4.84M 6.33M
Long term debt - - - - -
Inventory 7.14M 4.43M 3.72M 3.84M 0.20M
Accounts payable 2.43M 2.87M 0.76M 1.12M 1.10M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.32M -2.18800M -2.18800M -2.18800M -2.18800M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.52M 1.64M 1.72M 1.04M 0.95M
Deferred long term asset charges - - - - -
Non current assets total 28.03M 14.65M 7.51M 6.39M 10.29M
Capital lease obligations 6.82M 5.62M 0.47M 0.49M 0.75M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -15.76600M 30.31M -1.52600M 42.17M -40.00000M
Change to liabilities - - - 0.79M 2.33M
Total cashflows from investing activities -18.93566M 30.31M -37.40900M 42.17M -42.21600M
Net borrowings -0.83200M -0.42400M -0.27100M -0.53300M -0.47500M
Total cash from financing activities -2.39659M 18.26M -1.02600M -1.54600M 41.52M
Change to operating activities - - - -0.10500M -0.41100M
Net income 8.26M 2.92M -4.19700M -13.34900M -6.46200M
Change in cash -11.63986M 58.83M -37.06100M 30.66M -0.04000M
Begin period cash flow 79.60M 10.52M 47.58M 16.92M 16.96M
End period cash flow 67.97M 69.34M 10.52M 47.58M 16.92M
Total cash from operating activities 19.51M 10.30M 1.28M -9.75900M 0.88M
Issuance of capital stock 0.00000M 16.35M 0.00000M - 42.26M
Depreciation 1.66M 1.77M 1.34M 1.53M 1.69M
Other cashflows from investing activities - 0.08M -35.02200M -0.02100M 0.02M
Dividends paid - - - - -
Change to inventory -2.15303M -0.92000M -0.50600M -3.59500M -0.41100M
Change to account receivables 0.66M -0.86700M 1.09M 1.46M -0.84900M
Sale purchase of stock - 0.00000M 0.00000M -0.05200M -
Other cashflows from financing activities -1.56459M 2.33M -0.75500M -0.96200M -0.26900M
Change to netincome - - - 3.51M 4.59M
Capital expenditures 1.89M 3.79M 2.39M 0.00000M 2.24M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 8.21M 2.39M 1.64M -1.45400M 1.07M
Stock based compensation 1.20M 1.44M 0.38M 1.47M 1.89M
Other non cash items 1.37M 1.24M 1.88M 1.72M 2.66M
Free cash flow 17.62M 6.50M -1.10300M -9.75900M -1.35400M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BRSYF
BrainsWay Ltd		 - -% 16.84 75.28 64.52 12.02 7.41 11.32 60.24
ABT
Abbott Laboratories		 -0.58 0.66% 87.83 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 -3.11 1.01% 304.69 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -0.07 0.09% 79.27 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -0.96 2.12% 44.33 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.

BrainsWay Ltd

16 Hartum St, Jerusalem, Israel, 9777516

Key Executives

Name Title Year Born
Dr. Christopher R. von Jako Ph.D. Pres & CEO 1969
Mr. Richard Scott Areglado Sr. VP & CFO 1964
Mr. Hadar Levy Sr. VP & COO 1974
Mr. Christopher J. Boyer Ph.D. VP of Global Marketing 1978
Mr. Avner Hagai Founder & Independent Vice-Chairman 1956
Prof. Abraham Zangen Co-Founder, Member of Scientific Advisory Board & Director 1970
Dr. Yiftach Roth Ph.D. Chief Scientist 1971
Mr. Menachem C. Klein Esq. VP, Gen. Counsel & Corp. Sec. NA
Dr. Aron Tendler Chief Medical Officer NA
Ms. Moria Ankri VP R&D 1984

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions